Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With Persistent HPV16 or 18 Infection of the Cervix

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With Persistent HPV16 or 18 Infection of the Cervix

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs JNJ 63682918 (Primary) ; JNJ 63682931 (Primary) ; JNJ 65195208 (Primary)
  • Indications Human papillomavirus infections
  • Focus Adverse reactions; First in man
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 09 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 11 Sep 2018 Planned initiation date changed from 7 Sep 2018 to 24 Sep 2018.
    • 14 Aug 2018 Planned initiation date changed from 3 Aug 2018 to 7 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top